Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by N0taP00pon Aug 29, 2023 6:22pm
265 Views
Post# 35610843

RE:RE:RE:RE:RE:RE:RE:Interim Data...

RE:RE:RE:RE:RE:RE:RE:Interim Data...Overall, though BTD submission moved one year from their original estimate, they have for the first time clearly stated the steps to get there and the data continues to look good. If all goes well and we don't get into the holiday crush (read: key people needed to compile or approve are not available), we should have BTD by the end of the year. My gut says mid Q1. Maybe another pharma notices the data and jumps in early.  Will continue to hold.  Nothing interesting to see for the next few months.  Curious to see how the shares will react tomorrow
Legit62 wrote: totally agree Enrique, it appears we are at the point of getting everything in order and our next news release will indicate we have BTD and AA with that data being so superior


<< Previous
Bullboard Posts
Next >>